奇美拉实验室被评为1.01亿美元XPRIZE健康寿命竞赛的半决赛选手，因其在健康老龄化方面的开创性创新而获此殊荣-动脉网

Kimera® Labs Named Semifinalist in $101 Million XPRIZE Healthspan Competition for Pioneering Innovations in Healthy Aging

CISION 等信源发布 2025-05-12 20:00



可切换为仅中文







Leading Exosome Biotechnology Company Advances in Global Effort to Extend Healthy Human Lifespan

领先的外泌体生物技术公司在全球延长人类健康寿命的努力中取得进展

MIRAMAR, Fla.

米拉玛，佛罗里达州

，

May 12, 2025

2025年5月12日

/PRNewswire/ --

Kimera Labs

金梅拉实验室

, Inc., the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious

公司，治疗性外泌体生物技术的先驱，自豪地宣布其被选为享有盛誉的半决赛选手。

$101 million

1.01亿美元

XPRIZE Healthspan

XPRIZE 健康寿命奖

competition. This milestone recognizes Kimera's groundbreaking work in developing cutting-edge exosome-based therapeutics aimed at significantly extending the healthy, active years of human life.

竞赛。这一里程碑标志着Kimera在开发尖端的基于外泌体的治疗药物方面取得了开创性的成果，旨在显著延长人类健康、活跃的寿命。

继续阅读

Focused Ultrasound can target specific areas of the brain allowing enhanced exosome uptake.

聚焦超声可以靶向大脑的特定区域，从而增强外泌体的摄取。

Increased numbers of exosomes are identifiable in regions of the hippocampus targeted by focused ultrasound.

在聚焦超声靶向的海马区可识别出外泌体数量增加。

The first light based image in the world of an Exosome using novel dSTORM fluorescence microscopy techniques as employed by Kimera Labs (PRNewsfoto/Kimera Labs Inc)

使用Kimera Labs采用的新型dSTORM荧光显微技术拍摄的世界首张外泌体光基图像（PRNewsfoto/Kimera Labs Inc）

The original XPRIZE, awarded in 2004, created a new model for solving big challenges in an open, incentive-based competition. By offering

最初的 XPRIZE 于 2004 年颁发，开创了一种通过开放的、基于激励的竞争来解决重大挑战的新模式。通过提供

$10 million

1000万美元

for private spaceflight, it sparked the commercial space industry and proved that bold goals, clear rules, and global participation could drive breakthrough innovation across any field.

对于私人太空飞行来说，它激发了商业太空产业的发展，并证明了大胆的目标、明确的规则和全球参与可以推动任何领域的突破性创新。

XPRIZE Healthspan, launched by XPRIZE in 2023, is a global initiative designed to accelerate breakthroughs in science and technology that enhance human healthspan—the period of life spent in good health.

2023年，XPRIZE推出了XPRIZE Healthspan，这是一项旨在加速科学和技术突破的全球倡议，这些突破能够提升人类的健康寿命，即在良好健康状态下生活的时期。

Kimera Labs'

金梅拉实验室

advancement to the semifinalist stage places it among the top 40 teams selected from over 660 registered applicants across 58 countries—an elite group of innovators working to transform the future of aging and healthcare.

进入半决赛阶段，使其成为从58个国家超过660名注册申请者中选出的前40支团队之一——这是一群致力于改变老龄化和医疗保健未来的精英创新者。

Founded in 2012,

成立于2012年，

Kimera Labs

金迈拉实验室

is internationally recognized for its groundbreaking clinical-grade exosome products and leadership in regenerative science. Using an FDA-approved, pre-COVID single-donor perinatal MSC cell line, Kimera produces purified, cell-free exosome biologics in its 27,000 sq. ft. FDA-inspected, cGMP facility in .

因其开创性的临床级外泌体产品和在再生科学领域的领导地位而受到国际认可。Kimera使用经FDA批准的、新冠前的单供体围产期MSC细胞系，在其27,000平方英尺的FDA检查过的cGMP设施中生产纯化的无细胞外泌体生物制品。

Miami

迈阿密

, setting a new standard for purity, safety, and potency. Its flagship product, XoGlo®, is approved for Phase I/IIa clinical trials targeting post-COVID Acute Respiratory Distress Syndrome (ARDS), underscoring Kimera's commitment to advancing validated therapies for tissue regeneration, immune modulation, and healthy aging..

，为纯度、安全性和效力设定了新的标准。其旗舰产品XoGlo®已获批进行针对新冠肺炎后急性呼吸窘迫综合征（ARDS）的I/IIa期临床试验，彰显了Kimera致力于推进组织再生、免疫调节和健康老龄化的有效疗法的承诺。

'We are honored to be recognized as a semifinalist in XPRIZE Healthspan,' said

“我们很荣幸被评为XPRIZE Healthspan的半决赛选手，”

Duncan Ross

邓肯·罗斯

, PhD, Founder and CEO of

，哲学博士，创始人兼首席执行官

Kimera Labs

奇美拉实验室

. 'This achievement reflects our team's decade-long dedication to scientific excellence, innovation, and our mission to harness the potential of exosomes to enhance human health and longevity. The potential to live past 100 years, or even to 300, exists today, and the collaborations that will be born of this XPRIZE competition will get us there.'.

“这一成就反映了我们团队十年来对科学卓越、创新以及我们利用外泌体潜力来提升人类健康和寿命的使命的执着追求。活过100岁，甚至达到300岁的潜力在今天已经存在，而这场XPRIZE竞赛将孕育的合作关系将带领我们实现这一目标。”

As part of the competition,

作为比赛的一部分，

Kimera Labs

金梅拉实验室

has partnered with

与...合作

Sheldon Jordan

谢尔登·乔丹

, MD, and the Regenesis Project to combine its hyper-isolated perinatal exosome technology with low-intensity focused ultrasound targeting the brain. This novel platform has shown promising preclinical results, published by the group in

医学博士和Regenesis项目合作，将其高隔离的围产期外泌体技术与针对大脑的低强度聚焦超声相结合。这个新颖的平台已经显示出令人鼓舞的临床前结果，并由该团队发表在刊物上。

Nature Scientific Reports

自然科学报告

in October of 2023, unlocking the potential to mitigate age-related diseases, promote tissue regeneration, and enhance overall vitality.

2023年10月，解锁了减轻与年龄相关疾病、促进组织再生和增强整体活力的潜力。

'XPRIZE Healthspan is a pivotal opportunity to advance global health,' said Dr. Jordan. 'We are excited to join forces with

“XPRIZE Healthspan 是推动全球健康的关键机会，”乔丹博士说。“我们很高兴能够与

Kimera Labs

金默拉实验室

to accelerate the development of transformative breakthroughs in healthy aging.'

加速健康老龄化领域变革性突破的发展。

XPRIZE Healthspan will culminate in 2030 with the awarding of the grand prize to the team that demonstrates the most promising and scalable solution for extending healthspan and improving quality of life worldwide.

XPRIZE Healthspan 将于2030年迎来高潮，届时将向展示出最具前景且可扩展的延长健康寿命并改善全球生活质量方案的团队颁发大奖。

About

关于

Kimera Labs

金梅拉实验室

, Inc.:

公司：

Founded by Duncan Ross PhD in 2012,

2012年由邓肯·罗斯博士创立，

Kimera Labs

金梅拉实验室

is a leading clinical stage exosome biotechnology company specializing in the development of exosome therapeutics. Leveraging an FDA-approved single-donor pre-covid perinatal MSC cell line and over a decade of scientific leadership, Kimera operates out of a 27,000 sq. ft., FDA-inspected GMP-certified facility in .

是一家处于临床阶段的外泌体生物技术领先公司，专注于外泌体治疗的开发。依托经FDA批准的单供体新冠前围产期MSC细胞系以及十多年的科学领导地位，Kimera在一处27,000平方英尺、经FDA检查的GMP认证设施中运营。

Miramar, Florida

米拉玛，佛罗里达州

. Kimera is advancing the frontier of exosome science with a steadfast commitment to innovation, precision, and improving human health across the lifespan.

Kimera致力于通过坚定的创新、精准和改善人类全生命周期健康的承诺，推动外泌体科学的前沿发展。

About The Regenesis Project:

关于再生计划：

The Regenesis Project by neurologist

神经学家的再生计划

Sheldon Jordan

谢尔登·乔丹

MD is actively engaged in numerous clinical research studies that give patients access to cutting edge therapeutic modalities including focused ultrasound, TMS, and light therapy. Our ongoing clinical trials cover conditions such as dementia, Parkinson's disease, traumatic brain injury, anxiety, depression, and OCD as well as chronic pain and coma..

MD积极参与众多临床研究，为患者提供包括聚焦超声、经颅磁刺激（TMS）和光疗在内的前沿治疗方式。我们正在进行的临床试验涵盖痴呆、帕金森病、创伤性脑损伤、焦虑、抑郁、强迫症以及慢性疼痛和昏迷等疾病。

About XPRIZE:

关于XPRIZE：

XPRIZE is the recognized global leader in designing and executing large-scale competitions to solve humanity's greatest challenges. For over 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future.

XPRIZE是设计和执行大规模竞赛以解决人类最大挑战的全球公认领导者。三十多年来，我们独特的模式推动了众包创新和科学上可扩展的解决方案，加速迈向一个更加公平和富足的未来。

Donate, learn more, and co-architect a world of abundance with us at .

捐赠、了解更多，并与我们共同构建一个富足的世界。

xprize.org

。

About Exosomes:

关于外泌体：

Exosomes are 80-130nm secretions from all cell types that carry signaling cargo such as proteins and RNA.

外泌体是所有细胞类型分泌的80-130纳米的囊泡，携带蛋白质和RNA等信号货物。

Kimera Labs

金默拉实验室

develops exosome products from many cell sources including Mesenchymal Stem Cells for therapeutic use. Learn more about exosomes at exosomes.com.